An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Public ClinicalTrials.gov record NCT01868893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01868893
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Chlorambucil Drug
- Obinutuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2013
- Primary completion
- Dec 31, 2013
- Completion
- Dec 31, 2013
- Last update posted
- Apr 16, 2017
2013 – 2014
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| University of California San Diego | La Jolla | California | 92093 | — |
| Bay Area Cancer Research Group, LLC | Pleasant Hill | California | 94523 | — |
| Cancer Center of Central Conn. | Southington | Connecticut | 06489 | — |
| Peachtree Hematology & Oncology Consultants, Pc | Atlanta | Georgia | 30318 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Kootenai Cancer Center | Coeur d'Alene | Idaho | 83814 | — |
| Illinois Cancer Care, P.C. - Galesburg | Galesburg | Illinois | 61401 | — |
| Joliet Oncology Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Charleston Hematology Oncology | Charleston | South Carolina | 29414 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Vince Lombardi Cancer Clinic Pharmacy | Green Bay | Wisconsin | 54311 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01868893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2017 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01868893 live on ClinicalTrials.gov.